PAD Profile : Azathioprine - Oral disease indications

PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Azathioprine - Oral disease indications

PAD Profile : Azathioprine - Oral disease indications

Keywords :

RMOC, national shared care, Behcet's Disease, refractory inflammatory oral disease

Brand Names Include :

Imuran

Traffic Light Status

Status 1 of 1.

Status :

Amber

Formulations :

Oral suspension
Tablets

Trust Alignment :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

BNF NICE SPC

Comments :

No comments returned.

Documents :

Guidelines

No guidelines returned.

Other Drugs

Mycophenolate mofetil

Other Indications

Additional Documents

Type

Document

Review Date

Shared Care

Shared Care Request letter (Specialist to Primary Care Prescriber) - National Shared Care - Appendix 1

Shared Care

Azathioprine and 6MP for non-transplant indications -National shared care - update Aug 23

01 January 2025

Shared Care

Shared Care Agreement Letter (Primary Care Prescriber to Specialist)- National Shared Care - Appendix 2

Shared Care

Shared Care Refusal Letter (Primary Care Prescriber to Specialist)- National Shared Care - Appendix 3

Committee Recommendations

Date

Committee Name

Narrative

05 October 2022

Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) has agreed the National Shared Care Protocol for azathioprine and mercaptopurine for patients in adult services (non- transplant indications)

Associated BNF Codes

08. Malignant Disease and Immunosuppression

08.02.01. Antiproliferative immunosuppressants